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Abstract
The family of trace amine-associated receptors (TAAR) comprises 9 mammalian TAAR subtypes, with intact gene and
pseudogene numbers differing considerably even between closely related species. To date the best characterized subtype is
TAAR1, which activates the Gs protein/adenylyl cyclase pathway upon stimulation by trace amines and psychoactive
substances like MDMA or LSD. Recently, chemosensory function involving recognition of volatile amines was proposed for
murine TAAR3, TAAR4 and TAAR5. Humans can smell volatile amines despite carrying open reading frame (ORF) disruptions
in TAAR3 and TAAR4. Therefore, we set out to study the functional and structural evolution of these genes with a special
focus on primates. Functional analyses showed that ligands activating the murine TAAR3, TAAR4 and TAAR5 do not activate
intact primate and mammalian orthologs, although they evolve under purifying selection and hence must be functional. We
also find little evidence for positive selection that could explain the functional differences between mouse and other
mammals. Our findings rather suggest that the previously identified volatile amine TAAR3–5 agonists reflect the high
agonist promiscuity of TAAR, and that the ligands driving purifying selection of these TAAR in mouse and other mammals
still await discovery. More generally, our study points out how analyses in an evolutionary context can help to interpret
functional data generated in single species.
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Introduction
The trace amine-associated receptor family is a distinct
subfamily within the family of rhodopsin-like G protein-coupled
receptors (GPCR) and consists of 9 TAAR subtypes in mammals.
The subtype TAAR1 was the first deorphanized TAAR and
attracted attention because it is not only activated by trace amines,
namely b-phenylethylamine, p-tyramine and tryptamine, but also
by psychoactive compounds like MDMA, amphetamine and LSD
[1,2]. The signal transduction of TAAR1 is mediated by activation
of the Gs protein/adenylyl cyclase pathway. More recently, 3-
iodothyronamine, an endogenous derivative of thyroid hormones,
and metabolites of the antiarrhythmic drug amiodarone were
identified as agonists at TAAR1 [3,4]. It is of interest that there are
significant interspecies differences in functional and pharmacolog-
ical properties of TAAR1 [5,6,7].
Recently, expression of several other TAAR subtypes was
demonstrated in mouse olfactory epithelium. It was found that
murine TAAR3, TAAR4 and TAAR5 recognize volatile amines and
signal via Gs protein/adenylyl cyclases activation [8]. Similar to
odorant receptors, TAAR show differential expansions of gene
numbers among vertebrates [9,10,11]. Interestingly, humans do smell
volatileamines that activate murine TAAR3 and TAAR4, despitethe
fact that these 2 genes exhibit a disrupted open reading frame in
humans. Therefore we set out to study the evolution of TAAR3–5 in
mammals and primates. We tested whether these TAAR are
activated by the same volatile amines in different mammals and
investigated their sequence evolution among primates.
We found that the agonist profiles of TAAR3, TAAR4 and
TAAR5 vary significantly among mammals and that the agonists
identified in mouse are unlikely to be the natural agonists that are
responsible for the selective constraints observed among primates.
Further, we found that pseudogenization of TAAR is common
among primates and that changes in selective constraint of
TAAR3 and TAAR4 are correlated, suggesting that some as yet
unknown ecological factors might influence evolution of these
genes. In general, the observed differences in the functional TAAR
repertoire and agonist specificity may indicate species-specific or
physiological TAAR functions not yet identified.
Materials and Methods
TAAR ortholog identification
Mining of NCBI trace archives: TAAR sequences of various
mammalian species were obtained by using the respective mouse
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megablast and blasting all available mammalian trace archives.
Trace files of sequences producing significant alignments were
downloaded followed by assembly, analysis (using SeqManPro of
DNAStar Lasergene Software Suite for Sequence Analysis 7.1.)
and manual proof-reading. One exemplary trace identifier
number for each ortholog achieved is listed in Table S1.
Amplification, sequencing and cloning of TAAR orthologs: To
analyze the sequence of TAAR orthologs, genomic DNA samples
were prepared from tissue of various species (sources are given in
Table S2). Tissue samples were digested in lysis buffer (50 mM
Tris/HCl, pH 7.5, 100 mM EDTA, 100 mM NaCl, 1% SDS,
0.5 mg/ml proteinase K) and incubated at 55uC for 18 h. DNA
was purified by phenol/chloroform extraction and ethanol
precipitation. Degenerated primer pairs (Table S3) were applied
to amplify TAAR specific sequences. PCR reactions were
performed with Taq polymerase under variable annealing and
elongation conditions. A standard PCR reaction (50 ml) contained
genomic DNA (100 ng) with primers (1.5 mM each), ThermoPol
reaction buffer (1x), dNTP (250 mM, each) and Taq polymerase
(1 U, NEB, Frankfurt am Main, Germany). The reactions were
initiated with a denaturation at 95uC for 1 min, followed by 35
cycles of denaturation at 95uC for 30 s, annealing at 55uC for 30 s
and elongation at 72uC for 1 min. A final extension step was
performed at 72uC for 10 min. Specific PCR products were
directly sequenced and/or subcloned into the pCR2.1-TOPO
vector (Invitrogen, Paisley, UK) for sequencing. In case of
heterozygosity allelic separation was performed by subcloning
and subsequent sequencing. Sequencing reactions were performed
with a dye-terminator cycle sequencing kit and applied on a
MegaBACE
TM 1000 (GE Healthcare Europe GmbH, Munich,
Germany). All obtained TAAR3–5 sequences have been deposited
in the GenBank database (accession no. FJ372426–FJ372562,
FJ931100–FJ931115; Table S1).
The full length TAAR were inserted into the mammalian
expression vector pcDps and epitope-tagged with a N-terminal
hemagglutinin (HA) epitope and a C-terminal FLAG-tag by a
PCR-based overlapping fragment mutagenesis approach [12]. All
TAAR4 orthologs cloned for functional testing were additionally
tagged with a sequence encoding the N-terminal 20 amino acids of
bovine rhodopsin N terminus as described in [8]. All TAAR4
constructs contained the 12 C-terminal amino acids
(DSSTLSLFPALA) of the rhesus monkey TAAR4 as C terminus.
Identity of all constructs and correctness of all PCR-derived
sequences were confirmed by restriction analysis and sequencing.
Sequence alignments and PAML analyses
Primate TAAR3 (corresponding to amino acid positions 2.58–
7.70, relative numbering system of GPCR based on [13]), TAAR4
(amino acid positions 1.43–6.71) and TAAR5 (amino acid
positions 1.27–7.66) nucleotide alignments were generated with
the ClustalW algorithm (Bioedit Sequence Alignment Editor 7.0.9;
http://www.mbio.ncsu.edu/BioEdit/bioedit.html; [14]) followed
by manual trimming, whereupon frame-shifting insertions were
deleted. Stop codons and triplets that were affected by 1bp or 2bp
deletions in a respective ortholog were also deleted in all other
sequences included in the alignment. Phylogenetic relationship of
primates was inferred from our combined nucleotide TAAR3–4–5
sequence data. TAAR3–4–5 concatenation was accomplished to
increase sequence input for phylogenetic tree construction. Usage
of only primate TAAR3, TAAR4 and TAAR5 sequence data,
respectively, did not result in fully resolved trees (see Table S4).
Phylogenetic tree inference was conducted in MEGA4 [15] using
the Neighbor-Joining method [16] whereas the evolutionary
distances were computed applying the Maximum Composite
Likelihood method [17]. In addition, we determined phylogenetic
relationships from our combined TAAR3–4–5 nucleotide se-
quence data using Maximum Likelihood and the substitution
model F84 [18] as implemented in PHYLIP3.69 [19]. Branch
support was estimated with 1,000 bootstrap replicates [20]. The
resulting trees (Figure S1A, B) are not fully resolved indicated by
bootstrap values below 95%, but do not contradict other
reconstructions of primate phylogeny that use much more
sequence data [21]. Consequently, for PAML analyses we
assumed a primate phylogeny (Table S4) determined by [21].
Pseudogenes were removed from the respective trees for
performance of PAML analyses of primate TAAR3–5 ORF
lineages. Tests of selection (v=d N/dS) were accomplished by
maximum likelihood using a codon-based substitution model
implemented in PAML version 4.2 [22]. Branch models [23] that
allow v to vary among branches in the phylogeny were applied to
determine v ratios on particular lineages. Different site models
[24] that allow v to vary between sites were tested (models M1a,
M2a, M3, M7, M8). Comparison of 2 pairs of models was
performed: M1a and M2a, M7 and M8. Branch-site models were
applied to detect positive selection affecting only a few sites on pre-
specified foreground branches (test 2: modified model A versus
modified model A with v2=1 fixed) [25,26]. All analyses were run
twice using different initial v values to check for convergence.
Likelihood ratio tests (LRT) were performed to test nested
competing hypotheses.
Orthologous TAAR3, TAAR4 and TAAR5 full length
nucleotide sequences of 14 mammalian species (Table S1 all
species included are marked with *) were imported into Bioedit
Sequence Alignment Editor 7.0.9 (http://www.mbio.ncsu.edu/
BioEdit/bioedit.html) and aligned using ClustalW [14] followed
by manual trimming as stated above. Inference of phylogenetic
relationship of these 14 mammals from concatenated TAAR3–4–5
nucleotide sequence data using Neighbour-Joining and Maximum
Likelihood methods (see above for details) did not result in fully
resolved trees (Figure S2A, B). Hence, for PAML analyses
phylogenetic relations of these 14 mammals determined by [27]
was assumed. Different branch models [22], site models [24] and
branch-site models implemented in PAML version 4.2 were
applied [25,26] as described above.
Estimates of inactivation time and chances
The rate of inactivating mutations of TAAR sequences under
neutral evolution was determined by counting all pseudogeniza-
tion events in branches in which the respective TAAR is already
inactivated by deleterious mutations (frame-shifting indels, stop
codons) in its ancestral branch assuming the primate phylogeny as
stated above. Rates were calculated as events per unit of time using
divergence times of primate species as given in [28,29] and as
events per unit of dS distance. ReEVOLVER 1.0 was used to
determine the probability (Pdis) that the observed number of
deleterious mutations (stop codons, frame-shifting indels) is lower
or equal to what would be expected under neutral evolution [30].
Pdis is computed through comparison of the observed value with
the frequency distribution generated by simulation of neutral
evolution. An indel rate of 1.0610
210 per site per year and a
mutation rate of 1.0610
29 per site per year as suggested for Old
World monkeys [30] was used and 10,000 simulations were
performed.
Correlation of v in TAAR paralogs
A phylogenetic tree was constructed containing only primate
species for which sequences of all 3 receptors, TAAR3, TAAR4
TAAR Evolution
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implemented in PAML was used to calculate a separate v value
for each branch for each receptor (Table S4). A Spearman rank
correlation was performed on v values using GraphPad Prism
version 5.01 to pairwise evaluate association of evolution between
TAAR3, TAAR4 and TAAR5. Branches which showed dS=0
(absence of synonymous changes, leading to odd v values meaning
infinity) or branches which showed dN=0 (absence of non-
synonymous changes, meaning that v values approximate 0) were
excluded from analyses.
Cell culture and functional assays
HEK293 cells were grown in Minimum Essential Medium
(MEM) supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin at 37uCi nah u m i d i f i e d7 %
CO2 incubator. One day prior to transfection cells were split
into 50-ml cell culture flasks (1.4x10
6 cells/flask) and, for the
ALPHAScreen
TM cAMP assay, transfected with a total amount of
4 mg plasmid. For the CRE-SEAP (secreted alkaline phosphatase)
reporter gene assay cells were co-transfected (3 mgo fe a c h )w i t h
the TAAR expression plasmid and the CRE-SEAP reporter plasmid
(Clontech, Saint-Germain-en-Laye, France). Lipofectamine
TM 2000
(Invitrogen, Paisley, UK) was used for transient transfection of
HEK293 cells.
ALPHAScreen
TM cAMP assay: cAMP content of cell extracts
was determined by a non-radioactive cAMP accumulation assay
based on the ALPHAScreen
TM technology according to the
manufacturers’ protocol (Perkin Elmer LAS, Rodgau-Ju ¨gesheim,
Germany) [31]. One day after transfection cells were split into 48-
well plates (8x10
4 cells/well). Stimulation with various agonist
concentrations (all compounds from Sigma-Aldrich, Seelze,
Germany) was performed 48 h after transfection. Reactions were
stopped by aspiration of media and cells were lysed in 50 ml of lysis
buffer containing 1 mM 3-isobutyl-1-methylxanthine. From each
well 5 ml of lysate were transferred to a 384-well plate. Acceptor
beads (in stimulation buffer without 3-isobutyl-1-methylxanthine)
and donor beads were added according to the manufacturers’
protocol.
CRE-SEAP-reporter gene assay: One day after transfection
HEK293 cells were split into 96-well plates (4x10
4 cells/well) and
serum-free medium with no and increasing concentrations of
compounds was added the following day. Cells were incubated for
24 h at 37uC and then for 2 h at 65–70uC. An aliquot of the
supernatant from each well was then incubated (2–5 min, 21uC)
with an equal volume of 1.2 mM 4-methylumbelliferyl phosphate
(Sigma-Aldrich, Seelze, Germany) in 2 M diethanolamine bicar-
bonate with 1 mM MgCl2 and 4.5 mg/ml L-homoarginine
(pH 10) and fluorescence was measured with a Victor 2–1420
Multilabel counter (Perkin Elmer LAS, Rodgau-Ju ¨gesheim,
Germany).
Both cyclic AMP accumulation data and CRE-SEAP-reporter
gene assay data were analyzed using GraphPad Prism version 5.01
for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com).
Results
Evolution of open reading frame disruptions in TAAR3,
TAAR4 and TAAR5
Full length or partial TAAR3, 4 and 5 sequences of altogether
103 species were obtained by cloning and sequencing various
mammalian orthologs in particular from primates, and by mining
public sequence databases for additional orthologous sequences
(Table S1). To map mutational events we used the primate
phylogeny as stated in [21]. All 3 genes show mutational events on
different lineages that disrupt the ORF (Figures 1, 2 and 3).
Disruptions of TAAR3 ORF are caused by 7 independent events,
3 in apes and 4 in New World monkeys, 3 of which occurred in the
family Callithrichinae (Figure 1, Figure S3). A similar pattern is seen
for the 4 independent disruptions of TAAR4 (Figure 2, Figure S4).
ORF disruptions in TAAR5 occurred only in the gibbon lineage
and the lineage leading to the tarsier (Figure 3, Figure S5). In
contrast to primates, only very few ORF disruptions were detected
in other mammals analyzed. We found that 1 out of 25 non-
primate species carry a TAAR3 or a TAAR5 pseudogene. For
TAAR4 100 species (31 Primates,1 1Glires,1Scandentia,2 1
Carnivora,4Perissodactyla,1 1Cetartiodactyla,5Chiroptera,4Insectivora,
3 Xenarthra,6Afrotheria,2Metatheria,1Protheria) were analyzed. We
detected 10 TAAR4 pseudogenes (out of 31) in primates, but only
1 (out of 21) in Carnivora.O f6Afrotheria, only Caribbean manatee
and lesser hedgehog tenrec carry a TAAR4 pseudogene whereas
the latter possess an additional intact copy of TAAR4. Western
European hedgehog and European shrew exhibit also both 1
intact and 1 pseudogene TAAR4 copy. In sum, we observed ORF
disruptions also in other mammals, but significantly less frequent
than in primates (Table S1).
Functional characterization of selected mammalian
TAAR3, TAAR4 and TAAR5 orthologs
Since agonists for mouse TAAR3–5 have been identified [8], we
next asked whether these agonists also activate intact orthologs of
other mammals. In addition to the mouse TAAR3–5, which
served as positive control, we included the rat TAAR3–5 as
orthologs from another rodent species, selected primate TAAR3–5
containing intact ORF and at least one ortholog from a non-
primate/non-rodent species like cow, dog or northern treeshrew in
functional analyses. It was previously shown using a CRE-SEAP
reporter gene assay that isoamylamine and cyclohexylamine
stimulate intracellular cAMP formation via activation of the
mouse TAAR3 [8]. Whereas we found activation of mouse
TAAR3 by these agonists in a CRE-SEAP reporter gene assay,
none of the tested intact primate TAAR3 orthologs (hamadryas
baboon, rhesus monkey, emperor tamarin) displayed activity
(Figures 4A, B). Furthermore, the bovine TAAR3 did not show
any detectable activity and even the rat TAAR3, which is 95.6%
identical to the mouse TAAR3 protein, exhibited much lower
efficacy and potency to both agonists (Figures 4A, B).
It has been shown that agonistic properties of ligands can differ
considerably between the CRE-SEAP reporter gene assay and
classical cAMP accumulation assays [32]. Therefore, TAAR3
orthologs were additionally tested in an ALPHAScreen
TM
proximity assay where accumulated cAMP is measured directly.
Surprisingly, neither the murine TAAR3 nor the other TAAR3
orthologs tested displayed cAMP production following incubation
with cyclohexylamine (Figure 5A) and isoamylamine (data not
shown) although the assay worked properly with TAAR4 and
TAAR5 (Figures 5B, C).
It was demonstrated that the murine TAAR4 couples to the Gs
protein/adenylyl cyclase pathway and is activated by b-phenyl-
ethylamine when N-terminally tagged with 20 amino acids of the
bovine rhodopsin N terminus [1,8]. Consistent with this, we found
that b-phenylethylamine acts as agonist at the mouse, rat and
northern treeshrew TAAR4 orthologs in both the CRE-SEAP
reporter gene assay and the cAMP accumulation assay (Figures 4C,
5B). However, no activation by b-phenylethylamine was observed
for the 3 tested intact primate TAAR4 orthologs (Figure 4C).
Di- and trimethylamine act as agonists at mouse, rat
(Figures 4E, F) and dog TAAR5 (data not shown). Nonetheless,
TAAR Evolution
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intact ORF revealed that only the ring-tailed lemur and patas
monkey TAAR5 orthologs can be activated by di- and
trimethylamine to a marginal extent (Figures 4E, F). Both
methylamines displayed no agonistic activity at all other tested
primate (Figures 4E, F) and cow TAAR5 (data not shown) in the
CRE-SEAP reporter gene assay. In cAMP accumulation assays
di- and trimethylamine were agonists at the mouse, rat and dog
TAAR5, but no activation was found for the ring-tailed lemur
and patas monkey orthologs (Figure 5C).
In summary, we found that the agonists identified for mouse
TAAR3–5 are generally not agonists at primate TAAR3–5. To
gain further insight into the forces that might influence the
evolution of TAAR3–5 in primates we analyzed their patterns of
sequence evolution.
Sequence evolution of TAAR3, TAAR4 and TAAR5 in
primates
Although the structural conservation of intact TAAR on the
amino acid level is similar to other GPCR (Table S5) our
functional analyses revealed that agonist specificity for volatile
amines is much less conserved. This can be explained by different
scenarios. A first possibility is that even obviously intact TAAR
contain inactivating missense mutations, but have just by chance
not acquired ORF disruptions, yet. A second possibility is that
changes in agonist specificity were advantageous during evolution,
i.e. that positive selection acted on some TAAR to recognize
ligands other than the known mouse agonists. A third possibility is
that intact TAAR are activated by a yet unknown endogenous
agonist and the volatile amines are promiscuous agonists,
identified by chance. Evidence for and against these hypotheses
Figure 1. Phylogenetic tree of primate TAAR3 orthologs analyzed for open reading frames in the present study. The tree is based on
generally accepted primate phylogeny as described in [21]. Events causing pseudogenization (nucleotide insertions (ins) or -deletions (del) or stop
mutations (stop)) were determined and are labeled on the affected branches in red. Positions stated correspond to codon position of the respective
mouse ortholog. Pseudogenes are indicated as y and highlighted in red. Detailed information about the sequence changes causing
pseudogenization are in Figure S3. dN/dS-ratios (v) for each branch were calculated by using a ‘‘free ratio’’ model implemented in PAML and are
shown in bold below the branches. The number of non-synonymous and synonymous substitutions is given in parentheses. 6indicates branches
that were labeled to determine vy2 (see Table 1, Table S6).
doi:10.1371/journal.pone.0011133.g001
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fixations, so we estimated dN/dS ratios (v) across the different
primate lineages.
The dN/dS ratio is the number of non-synonymous substitu-
tions per non-synonymous site (non-synonymous substitution
rate dN) normalized to the number of synonymous substitutions
Figure 2. Phylogenetic tree of all primate TAAR4 orthologs analyzed for ORF. The tree is based on generally accepted primate phylogeny
as described in [21]. Events causing pseudogenization (nucleotide insertions (ins) or -deletions (del) or stop mutations (stop)) are indicated in red on
the affected branches. Positions stated correspond to codon position of the respective mouse ortholog. Pseudogenes (y) are highlighted in red.
Emperor tamarin was found to be polymorphic. Detailed information about pseudogenization events is in Figure S4. A ‘‘free ratio’’ model
implemented in PAML was used to calculate dN/dS-ratios (v shown in bold below branches) and the number of non-synonymous and synonymous
substitutions (shown in parentheses) for each branch. 6indicates branches that were labeled to determine vy2 (see Table 1, Table S6) # indicates
branches labeled in branch model/branch-site model to determine vcerc.
doi:10.1371/journal.pone.0011133.g002
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protein evolves under no constraint, i.e. is a pseudogene and has
no function, it is expected to show an v of 1, since synonymous
mutations get fixed as frequently as non-synonymous mutations.
Most proteins show an v well below 1, since most mutations
that lead to amino acid substitutions decrease fitness and hence
a r eu n l i k e l yt ob e c o m ef i x e dbetween species (purifying
selection). In contrast, amino acid substitutions that are
positively selected are more likely to become fixed and repeated
positive selection can be detected by an v significantly larger
than 1. We used PAML to estimate v and compare different
codon substitution models in a maximum-likelihood framework
[22,33]. Note however, that absence of evidence for positive
selection in PAML does not rule out presence of positive
selection since e.g. positive selection acting rarely on one or a
few sites is unlikely to be detected [34].
To investigate the first scenario, we tested whether intact
primate TAAR3–5 ORF evolve under purifying selection by
comparing different models (Table 1, Table S6). We found that a
model in which lineages that contain ORF disruptions have a
different v to all other lineages is strongly favored for TAAR3 and
TAAR4 (model B versus model C, Table 1, Table S6). In the case
of TAAR5 there are just 2 lineages with ORF disruptions whereas
one is the long branch leading to the Philippine tarsier. This
lineage has a rate significantly smaller than 1 (model D versus
model C, Table 1, Table S6). This can be readily explained if the
loss of constraint and the subsequent ORF disruption occurred a
substantial time after the divergence of the lineage, since in this
Figure 3. Phylogenetic tree of primate TAAR5 orthologs analyzed for ORF. The tree is based on generally accepted primate phylogeny as
described in [21]. ORF disruptions (y highlighted in red) are only found in Philippine tarsier (1bp deletion) and white- and yellow-cheeked gibbon
TAAR5 (4bp insertion and 1bp deletion). Positions stated correspond to codon position of the respective mouse ortholog. Detailed information about
pseudogenization events is depicted in Figure S5. Below the branches, dN/dS-ratios (v) that were determined by using a ‘‘free ratio’’ model
implemented in PAML are shown. The number of non-synonymous and synonymous substitutions is indicated in parentheses.6indicates branches
that were labeled to determine vy2 (see Table 1, Table S6).
doi:10.1371/journal.pone.0011133.g003
TAAR Evolution
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under constraint and later neutral evolution. Therefore, we
distinguished branches that had an ORF disruption acquired
already in an ancestral branch (y1 lineages) from lineages along
which a pseudogenization event occurred (y2 lineages, see
Figures 1, 2 and 3). In such a model the y1 lineages indeed
evolve at a rate that is not different from 1 as expected (model G
versus model F, Table 1, Table S6). Lineages with intact ORF
evolve at rates significantly (p,0.0001) smaller than 1 (model E
versus model C, Table 1, Table S6) and we estimate these rates to
be 0.128, 0.274 and 0.213 for TAAR3, TAAR4 and TAAR5,
respectively (model C, Table S6). Taken together, these analyses
clearly show that TAAR pseudogenes evolve without constraint
and TAAR with intact ORF evolve under constraint, making it
very unlikely that the observed functional differences result from
intact but non-functional TAAR in primates. However, for
individual branches it is in principle still possible that the loss of
constraint occurred very recently, and that while missense
mutations led to a change or loss of functionality as demonstrated
in other GPCR [35], ORF disruptions have by chance not yet
occurred. Therefore, we estimated the average time for acquiring
at least one ORF disrupting mutation in TAAR3–5 under neutral
Figure 4. Functional characterization of mammalian TAAR3, TAAR4 and TAAR5 orthologs using a CRE-SEAP reporter gene assay.
HEK293 cells were transiently co-transfected with CRE-SEAP reporter plasmid (Clontech) and respective receptor orthologs and tested for agonist-
induced SEAP-activity. The basal value of non-stimulated mock-transfected HEK293 determined was 193,208621,052 cpm/well. Data are given as
mean6SEM of 2 to 5 independent experiments each performed in triplicates. Concentration-response curves of agonists were determined using
GraphPad Prism.
doi:10.1371/journal.pone.0011133.g004
TAAR Evolution
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11133evolution. The decisive parameter hereby is the rate of frame-shift
mutations since these are more likely to occur than stop mutations
[36]. Frame-shift mutations depend strongly on sequence context,
as can be seen in 4 independent insertion and deletion events in
the TAAR4 poly-A stretch at codon position 247–249 (Figure 2,
Figure S4). We used the empirical rate of pseudogenization events
that occurred in all lineages of TAAR3–5 that had already
acquired an ORF disruption in an ancestral lineage. We estimate
that an ORF disruption occurs once every 7.362.7 million years
(myr) (assuming a Poisson distribution) or once per 2.261.7
synonymous substitutions. Hence, it is not very likely but in
principle possible that some of the tested intact primate TAAR are
non-functional due to a recent loss of constraint and inactivating
missense mutations. However, it is extremely unlikely that all
tested intact primate TAAR are not activated by the mouse
agonists for this reason. A far more parsimonious explanation is
certainly that most if not all intact TAAR are functional since they
evolve under strong constraints and would acquire ORF
disruptions relatively quickly after losing this constraint.
The second scenario was examined by exploring evidence for
positive selection. We first tested whether models in which some
sites in intact TAAR evolve at rates larger than 1 explain the
sequence differences significantly better than models without such
sites (site models Table S6, Table S7). We found no evidence for
positively selected sites in primate TAAR3–5. Although, this does
not exclude that some positive selection occurred during primate
TAAR evolution, it argues against frequent positive selection
acting on the same sites within primates and therefore against
positive selection as a cause for agonist change within primates.
However, we found evidence for positively selected sites among 14
Figure 5. Functional characterization of mammalian TAAR3, TAAR4 and TAAR5 orthologs using a cAMP accumulation assay. Cells
were transfected with receptor orthologs and agonist-induced cAMP accumulation was determined with the ALPHAScreen
TM technology. (see
Material and Methods). The basal cyclic AMP level of non-stimulated mock-transfected HEK293 was 6.3561.02 amol/cell. Data are given as
mean6SEM of 2 independent experiments each performed in duplicates. Concentration-response curves of agonists were determined using
GraphPad Prism.
doi:10.1371/journal.pone.0011133.g005
Table 1. Likelihood ratio test (LRT) statistics comparing different models presented in Table S6 for analyses of pseudogene
evolution of TAAR3–5.
Hypothesis tested TAAR3 TAAR4 TAAR5
(models compared: null vs. alternative)
a v P-value v P-value v P-value
v0?vy v0=0.128 ,0.0001 v0=0.274 ,0.0001 v0=0.213 0.1198
(B vs. C) vy=0.878 vy=0.884 vy=0.319
v0, vy?1 v0=0.128 0.5967 v0=0.274 0.6390 v0=0.213 ,0.0001
(D vs. C) vy=1 vy=1 vy=1
v0?1, vy v0=1 ,0.0001 v0=1 ,0.0001 v0=1 ,0.0001
(E vs. C) vy=0.920 vy=0.903 vy=0.323
v0?vy v0=0.128 0.0444 v0=0.274 0.6714 v0=0.213 0.0119
vy?vy1?vy2 vy1=2.915 vy1=0.787 vy1=‘
(F vs. C) vy2=0.701 vy2=0.982 vy2=0.285
v0, vy1?1, vy2 v0=0.128 0.1089 v0=0.274 0.5271 v0=0.213 0.1153
(G vs. F) vy1=1 vy1=1 vy1=1
vy2=0.699 vy2=0.982 vy2=0.285
v0, vy1, vy2?1 v0=0.129 0.1871 v0=0.274 1 v0=0.213 ,0.0001
(H vs. F) vy1=2.924 vy1=0.787 vy1=‘
vy2=1 vy2=1 vy2=1
aLRT tests were performed between nested models. In parentheses designation for the compared models is given as indicated in Table S6. v,d N/dS ratio; v0, indicates v
of all other branches (the ones that are not specifically labeled in a model); vy1, v of branches being definitely under neutral evolution because of deleterious mutation
(pseudogenization) in ancestor branch; vy2, v of branches along which inactivating pseudogenization event occurred (see 6Figure 1–3); vy, v of all pseudogene
branches (y1 plus y2); ‘, v estimated to be infinite generated by dS=0 (absence of synonymous changes).
doi:10.1371/journal.pone.0011133.t001
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TAAR3 and TAAR4 (Table S6, Table S7). Moreover, we applied
the ‘‘free ratio’’ model implemented in PAML to determine v
values for each branch for each receptor for primates and
mammals (Figures 1, 2 and 3, Figure S7). Since multiple lineages
were evaluated this way, multiple testing is a potential problem for
inferring the significance of results. However, the analysis is still
useful for exploring branches especially if functional assays are
available to support claims about positive selection by additional
experiments. For TAAR3 of primates and other mammals there
are no lineages evolving at a suspiciously high rate. Thus, we find
no evidence at all that positive selection changed the agonist
profile of TAAR3. Moreover, non-function of cow TAAR3 and
primate TAAR3 argue against a single amino acid substitution as
a cause for the functional differences observed. Together with the
marginal and no activity of mouse and rat TAAR3 in the CRE-
SEAP reporter gene assay and the cAMP accumulation assay,
respectively, this suggests that the identified agonistic volatile
amines at TAAR3 are not the natural agonists.
For TAAR4, lineages of Cercopithecinae (rhesus monkey, mandrill,
hamadryas baboon and patas monkey) and Glires (rabbit, guinea
pig, rat and mouse) showed a high v. Application of a branch
model in which TAAR4 of Cercopithecinae were labeled as
foreground branch (see Figure 2) revealed a significantly higher
v (vcerc=2.590) compared to all other branches (Table 2).
However, TAAR4 in Cercopithecinae did not evolve at a rate
significantly larger than 1 and also showed no explicit evidence for
specific sites under positive selection (branch-site model, Table 2,
Table S6). Because higher v in Cercopithecinae can be taken as a
signal of neutral evolution we simulated neutral evolution using
ReEVOLVER 1.0 [30] and found that it is very unlikely to
observe no disrupting mutations in Cercopithecinae TAAR4
orthologs (Pdis=0.0006) within 55 myr of neutral evolution (or
7.2 synonymous substitutions, respectively). Similarly, TAAR4 of
Glires evolved with a significantly higher v (vglires=1.209) than all
other mammalian branches but not significantly different from 1
(Table 2). Using branch-site model A with the Glires branch (see
Figure S7B for labeling) as foreground lineage in the branch-site
test of positive selection (null model v2=1 fixed) LRT provided
marginally significant support (P=0.052) for 2 positively selected
sites with Bayes empirical Bayes (BEB) probability above 0.7
(Table 2). Therefore, there is some evidence that positive selection
might be responsible for different agonist profiles found for
TAAR4. Future attempts of deorphanization of TAAR4 in
primates and other mammals should take into account that
TAAR4 of some tailed Old World monkeys and rodents might
have a different function.
Finally, application of a ‘‘free ratio’’ model to TAAR5 of non-
primate mammals did not reveal signs of positive selection in any
branches. The same approach applied to primate TAAR5 with
intact ORF revealed a few branches with increased v values
(especially within apes and at the split of rhesus monkey and
hamadryas baboon). However, LRT failed to provide significant
support for positive selection along these branches (see Table 2)
and it is more parsimonious to assume that positive selection has
not changed the agonist profile of TAAR5 especially because no
function was observed in TAAR5 of different mammalian orders
(Primates, Cetartiodactyla). Overall, evolutionary and functional data
imply that agonist profiles changed frequently in TAAR5 and that
the volatile amines are species-specific surrogate but not the
natural agonists.
In sum, phylogenetic sequence analyses neither strongly
support the first nor the second scenario as explanations for the
fact that primate TAAR are not activated by the respective
mouse agonists. This leaves the third scenario as most likely
explanation which we further investigated by searching com-
pound libraries for additional agonists at murine TAAR3–5 using
CRE-SEAP reporter gene assays. We identified naphazoline (see
Figure 4D), xylometazoline and b-methylphenylethylamine (see
Figure S6) as agonists at mouse TAAR4. These substances also
activated rat and northern treeshrew, but not primate TAAR4
(data not shown). These findings clearly demonstrate agonist
promiscuity at least for TAAR4 which has also been shown for
TAAR1 by previously published functional data [5,6,7]. It is
therefore reasonable to assume that volatile amines act as
promiscuous agonists at some TAAR3 and TAAR5 orthologs,
Table 2. Likelihood ratio test (LRT) statistics for testing
hypotheses (models shown in Table S6) concerning positive
selection in certain species of TAAR4 and changing constraint
in TAAR5.
Hypothesis tested v P-value
TAAR4
branch models
v0?vcerc v0=0.247 ,0.0001
vcerc=2.590
v0, vcerc?1 v0=0.247 0.1626
vcerc=1
v0?vglires v0=0.172 0.0477
vglires=1.209
v0, vglires?1 v0=0.172 0.8875
vglires=1
branch site models
model A versus model A’ v0=0.153 0.1389
(foreground branch: cerc) v1=1
v2(cerc) =3.722
v2a(othprim) =0.153
v2b(othprim) =1
model A versus model A’ v0=0.079 0.0525
(foreground branch: Glires) v1=1
v2(glires) =42.11
v2a(othmam) =0.079
v2b(othmam) =1
TAAR5
branch models
v0?vhcg v0=0.204 0.0676
vhcg = 0.537
v0, vhcg?1 v0=0.205 0.2542
vhcg=1
v0?vrp v0=0.213 0.2965
vrp=0.543
v0, vrp?1 v0=0.213 0.5169
vrp=1
vcerc, v of Cercopithecinae (see Figure 2 for labeling); vglires, v of Glires (see
Figure S7B for labeling); vhcg, v of human, chimp and gorilla; vrp, v of rhesus
monkey and hamadryas baboon; vothprim, v of all other primates except species
labeled as foreground branches in respective branch-site test of positive
selection; vothmam, v of all other mammals except species labeled as
foreground branches in branch-site test of positive selection.
doi:10.1371/journal.pone.0011133.t002
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these receptors.
Test for correlated evolution of TAAR3–5 in primates
Sequence analyses of primate TAAR3–5 for pseudogenization
events (see above) revealed an apparent overlap among species (in
apes and Callithrichinae) that carry TAAR3 and TAAR4 pseudo-
genes(Figures 1,2).Wethereforeexplored towhat extenttherate of
evolution is correlated among TAAR3–5 at the different primate
branches. Thus, lineages were grouped into 4 categories, in which
pseudogenization occurred in both TAAR3 and TAAR4 (category
1) or only in TAAR3 (category 2) or TAAR4 (category 3), or in
neither gene (category 4). We only included species in this test for
which sequence information is available for all 3 analyzed subtypes
(seeFigureS1)and found 3eventsincategory1,4 incategory 2,1 in
category3 and 31 incategory 4.We detected a significantoverlap of
pseudogene lineages between TAAR3 and TAAR4 (Fisher’s exact
test, P=0.01) whereas TAAR3 and TAAR5 or TAAR4 and
TAAR5 share no overlap (P=1). To further investigate the
potentially correlated evolution of TAAR3 and TAAR4, we
correlated v values for each branch generated by ‘‘free ratio’’
models in PAML (Table S4) to pairwise evaluate correlation of
TAAR evolution. We found a significant correlation of dN/dS ratios
of TAAR3 and TAAR4 (Spearmans’ rank rs=0.4870, P=0.0252)
whereas the 2 other combinations showed no correlation (TAAR3–
TAAR5, coefficient rs=0.3345, P=0.1383; TAAR4–TAAR5,
coefficient rs=0.3754, P=0.0935). This indicates that selective
pressures that differ among species affect the amount of constraint
actingonTAAR3andTAAR4ina similarmannerandthussuggest
a similar function of these 2 receptors.
Discussion
Mouse TAAR3, TAAR4 and TAAR5 agonists do not
account for purifying selection on intact primate
receptors
Recently, several volatile amines were found to activate several
murine TAAR subtypes including TAAR3 (isoamylamine, cyclo-
hexylamine), TAAR4 (b-phenylethylamine) and TAAR5 (di- and
trimethylamine) [8]. These findings were intriguing in assigning
TAAR as an important receptor class of the chemosensory system.
However, all humans carry only pseudogenes of TAAR3 and
TAAR4 but are nevertheless able to smell these amines,
questioning the generality of the findings for mouse TAAR.
Our studies confirmed the previously identified agonists at
murine TAAR3, TAAR4 and TAAR5 in the CRE-SEAP reporter
gene assays (see Figure 4). In contrast, most intact primate
TAAR3–5 showed no activation upon stimulation with the
respective amines. Only the ring-tailed lemur TAAR5 displayed
marginal activity when incubated with di- and trimethylamine (see
Figures 4E, F). A loss of agonist potency and/or efficacy is already
seen when mouse and rat TAAR3 and TAAR4 orthologs are
compared (see Figures 4A–D) indicating species-specific agonist
specificity. In case of TAAR4, this pharmacological difference is
caused by only a few amino acid differences (see Figure S8). The
CRE-SEAP reporter gene assay used by [8] is convenient but
cAMP formation is read out indirectly and downstream the
signaling cascade. Therefore, we tested whether the differences in
ortholog function are also present when cAMP formation upon
stimulation was measured directly in a cAMP accumulation assay.
Surprisingly, receptor activation was found for rat and mouse
TAAR4 and TAAR5 but not for any TAAR3 ortholog (see
Figures 5A–C). We speculate that the sensitivity of the CRE-SEAP
reporter gene assay is higher than that of the classical cAMP
accumulation assay. It has been demonstrated that CREB can be
activated also by other signal transduction pathways and results
from the CRE-SEAP reporter gene assay can differ when
compared with other second messenger assays [32,37]. Neverthe-
less, the fact that almost all primate and other intact mammalian
TAAR3–5 orthologs lacked activity upon agonist stimulation in
both assays implicates that the volatile amine agonists at the
murine TAAR are not the agonists for most other mammal and
primate orthologs.
We used phylogenetic sequence analyses to evaluate different
scenarios as explanation for these observed functional differences.
One possibility is that the tested mammalian and primate genes
are non-functional due to missense mutations despite their intact
ORF. However, the low v observed among primates and
mammals in general (see Table S6) together with the high
probability of obtaining ORF disruptions after a release of
constraint makes this scenario very unlikely. Another possibility
is that the physiological function of these TAAR may have
changed frequently during evolution. This is unlikely for TAAR3,
because we did not find any signs of positive selection. These
results together with the discrepancies in functional data obtained
on TAAR3 in different assays instead suggest that the previously
identified agonists are surrogate ligands but not the natural
agonists that drive purifying selection on this gene in mouse and
other mammals. For TAAR4 there are some indications for
positive selection in some tailed Old World monkeys and in Glires
(including rat and mouse). Thus, it is possible that the recognition
of the formerly identified agonist b-phenylethylamine is function-
ally relevant for Glires, but the agonist activating most other
mammalian TAAR4 still needs to be identified.
The hypothesis that the identified volatile amines are surrogate
agonists at TAAR3–5 is in line with the high ligand promiscuity of
TAAR1 [5,6,7]. In addition to trace amines (b-phenylethylamine,
p-tyramine, octopamine, tryptamine), other biologically active
compounds are potent and efficient TAAR1 agonists including
amphetamines and thyronamines among the most notable [38].
Similarly, we found naphazoline (Figure 4F), xylometazoline and
b-methylphenylethylamine (Figure S6), to be full or partial
agonists on several TAAR4 orthologs whereas many TAAR1
agonists (p-tyramine, octopamine, amphetamines) activate mouse,
rat and northern treeshrew TAAR4 either to much lesser extent or
not at all (data not shown).
Convergent evolution of TAAR3 and TAAR4 in apes and
Callithrichinae
One surprising discovery was that species carrying TAAR3 and
TAAR4 pseudogenes significantly overlap (Figures 1, 2). These
ORF disruptions very likely reflect a complete loss of function as
there is no evidence for constraint in these disrupted genes. Some
of those result from pseudogenization events on the same lineages
in both receptors, as for e.g. in the common ancestor of humans,
chimpanzees and gorillas and on the lineage to the white-handed
gibbon. In the 2 marmosets the loss of constraint occurred in their
common ancestor for TAAR3 and TAAR4 but inactivating
mutations occurred and became fixed before or after the lineage
split. Thus, TAAR3 and TAAR4 pseudogenization does not fully
correlate, as also seen for the lineage to orangutan and the woolly
monkey. However, both the partial overlap and the observed
correlation of constraint among TAAR3 and TAAR4 in intact
ORF lineages suggest that TAAR3 and TAAR4 have common
constraint-determining factors, and probably similar functions.
Our study suggests that agonists involved in this function should be
active in all or at least many primates. Further research on the
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physiological functions in mammals.
Conclusion
Our functional data for TAAR3, TAAR4 and TAAR5 revealed
a high species-specificity for the identified volatile amine agonists.
Since intact primate TAAR3–5 evolve under purifying selection
we suggest that the identified mouse TAAR3–5 agonists are
surrogate ligands but not the natural agonists. The correlated
evolution of TAAR3 and TAAR4 suggest similar agonists and
physiological functions for these 2 receptors.
More generally, the present study emphasizes the usefulness of
investigating function as well as sequence evolution in a wide range
of organisms to interpret functional studies in a single species.
Supporting Information
Figure S1 Phylogenetic trees of primate species inferred from
the combined TAAR3-TAAR4-TAAR5 sequence dataset. A:The
evolutionary history of 21 primates was inferred using the
Neighbor-Joining method [16]. The evolutionary distances were
computed using the Maximum Composite Likelihood model [17]
implemented in MEGA4 [15]. B: The phylogenetic relationship of
21 primates was inferred using the Maximum Likelihood method.
The F84 model [18] was specified and analyses were conducted by
using PHYLIP3.69 [19]. The bootstrap consensus trees inferred
from 1,000 replicates are taken to represent the evolutionary
history of the taxa analyzed [20]. The percentage of replicate trees
in which the associated taxa clustered together in the bootstrap test
(1,000 replicates) are shown next to the branches [20] The tree is
drawn to scale, with branch length corresponding to nucleotide
substitutions per site. All codon positions were included, all
postions containing gaps and missing data were eliminated from
the dataset. There were a total of 2289 nucleotides in the final
dataset.
Found at: doi:10.1371/journal.pone.0011133.s001 (0.96 MB TIF)
Figure S2 Phylogenetic trees of mammalian species inferred
from the concatenated TAAR3-TAAR4-TAAR5 sequence data-
set. A:The evolutionary history of 14 mammals was inferred using
the Neighbor-Joining method [16]. The evolutionary distances
were computed using the Maximum Composite Likelihood model
[17] implemented in MEGA4 [15]. B: The phylogenetic
relationship of 14 mammals was inferred using the Maximum
Likelihood method. The F84 model [18] was specified and
analyses were conducted by using PHYLIP3.69 [19]. The
bootstrap consensus trees inferred from 1,000 replicates are taken
to represent the evolutionary history of the 14 mammals analyzed
[20]. The percentage of replicate trees in which the associated taxa
clustered together in the bootstrap test (1,000 replicates) are shown
next to the branches [20] The trees are drawn to scale, with
branch length corresponding to nucleotide substitutions per site.
All codon positions were included, all postions containing gaps and
missing data were eliminated from the dataset. There were a total
of 3063 nucleotides in the final dataset.
Found at: doi:10.1371/journal.pone.0011133.s002 (0.65 MB TIF)
Figure S3 Primate TAAR3 pseudogenization. Events causing
pseudogenes (indicated with y) are depicted in bold. TAAR3 is
inactivated not only in apes except siamang but also in some New
World monkeys.
Found at: doi:10.1371/journal.pone.0011133.s003 (0.47 MB TIF)
Figure S4 Primate TAAR4 pseudogenization. TAAR4 is a
pseudogene (y) in all apes except orangutan and siamang and in 3
New World monkeys. Positions hit by insertions, deletions or stop
mutations are indicated in bold.
Found at: doi:10.1371/journal.pone.0011133.s004 (0.58 MB TIF)
Figure S5 Primate TAAR5 pseudogenization. TAAR5 is a
pseudogene in white- and yellow-cheeked gibbon and Philippine
tarsier. All other primate TAAR5 possess an intact ORF.
Nucleotide insertions or deletions causing pseudogenization (y)
are depicted in bold.
Found at: doi:10.1371/journal.pone.0011133.s005 (0.28 MB TIF)
Figure S6 Functional characterization of mouse TAAR4 using a
CRE-SEAP reporter gene assay. HEK293 cells were transiently
co-transfected with CRE-SEAP reporter plasmid (Clontech) and
mouse TAAR4 and tested for agonist induced SEAP-activity. The
basal value of non-stimulated mock-transfected HEK293 deter-
mined was 193,208621,052 cpm/well. Data are given as
mean6SEM of 2 independent experiments each performed in
triplicates. Concentration-response curves of agonists were deter-
mined using GraphPad Prism.
Found at: doi:10.1371/journal.pone.0011133.s006 (0.14 MB TIF)
Figure S7 Phylogenetic tree of 14 mammalian species. Phylo-
genetic tree is based on phylogeny described in [27]. dN/dS-ratios
(v) ratios for each branch using full length TAAR3 (A), TAAR4
(B) and TAAR5 (C) sequences of selected mammals were
calculated by using a ‘‘free ratio’’ model implemented in PAML
and are shown in italic above the respective branch. The number
of non-synonymous and synonymous substitutions for each branch
is shown in parentheses. Branch-site models were performed to
detect positive selected sites in certain branches. Foreground
branches are labeled with #.
Found at: doi:10.1371/journal.pone.0011133.s007 (0.52 MB TIF)
Figure S8 Serpentine model of TAAR4 rhodopsin constructs.
Amino acid sequence of mouse TAAR4 is shown. All constructs
possess a N-terminal HA- and a C-terminal FLAG-tag (light gray).
Each construct has additionally to its own N terminus the first 20
amino acids of bovine rhodopsin N terminus and a modified C
terminus corresponding to 12 C-terminal amino acids of the
rhesus monkey TAAR4 (depicted in dark gray). Amino acid
positions differing between mouse and rat TAAR4 are shown in
white.
Found at: doi:10.1371/journal.pone.0011133.s008 (0.24 MB TIF)
Table S1 NCBI database accession numbers and sequence
description.
Found at: doi:10.1371/journal.pone.0011133.s009 (0.24 MB
PDF)
Table S2 Sources of genomic DNA used for TAAR3, TAAR4
and TAAR5 amplification.
Found at: doi:10.1371/journal.pone.0011133.s010 (0.13 MB
PDF)
Table S3 Primers used for TAAR3, TAAR4 and TAAR5
ortholog amplification, sequencing and site-directed introduction
of epitope tags.
Found at: doi:10.1371/journal.pone.0011133.s011 (0.10 MB
PDF)
Table S4 Phylogenetic trees in NEWICK notation.
Found at: doi:10.1371/journal.pone.0011133.s012 (0.10 MB
PDF)
Table S5 Structural comparison of mammalian GPCR ortho-
logs. The amino acid sequence information of 8 full-length
orthologs (Bos taurus, Cavia porcellus, Echinops telfairi, Macaca mulatta,
Mus musculus, Oryctolagus cuniculus, Rattus norvegicus, Sus scrofa) of each
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PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e11133receptor was used to determine the structural conservation
between mammalian orthologs (given as % aa identity determined
by ClustalW implemented in MegAlign of Lasergene 7.1.) are
shown. Data are given as mean6S.D. ADRB1, beta-1-adrenergic
receptor; ADRB2, beta-2-adrenergic receptor; MC4R, melancor-
tin receptor 4; V2R, vasopressin type 2 receptor.
Found at: doi:10.1371/journal.pone.0011133.s013 (0.05 MB
PDF)
Table S6 Maximum likelihood estimates of dN/dS ratios (v) for
primate and 14 non-primate mammalian TAAR3, TAAR4 and
TAAR5 under different models using PAML.
Found at: doi:10.1371/journal.pone.0011133.s014 (0.19 MB
PDF)
Table S7 Likelihood ratio test (LRT) statistics for testing site-
specific models within primate ORF lineages and 14 non-primate
mammalians.
Found at: doi:10.1371/journal.pone.0011133.s015 (0.15 MB
PDF)
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